What is Semaglutide?

Semaglutide is a synthetic 31-amino-acid peptide analog of human glucagon-like peptide-1 (GLP-1) that shares 94% structural homology with native GLP-1(7-37). Developed by Novo Nordisk, it is one of the most extensively studied peptide therapeutics in history, with data from over 60,000 patients across multiple international trial programs. Semaglutide is FDA-approved under three brand names — Ozempic (type 2 diabetes), Wegovy (chronic weight management and cardiovascular risk reduction), and Rybelsus (oral formulation for type 2 diabetes).

What distinguishes semaglutide from native GLP-1 is its engineered resistance to degradation by dipeptidyl peptidase-4 (DPP-4). Two key modifications make this possible: an amino acid substitution at position 8 (Ala8 to Aib8) that blocks DPP-4 cleavage, and a C-18 fatty diacid chain attached via a linker at Lys26 that enables non-covalent albumin binding. Together, these modifications extend the half-life from approximately 2 minutes (native GLP-1) to approximately 7 days, enabling once-weekly dosing.

Mechanism of Action

GLP-1 Receptor Signaling Cascade

Semaglutide exerts its effects by binding the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, the cardiovascular system, the kidneys, and the central nervous system — particularly the hypothalamus and area postrema.

Primary Gs-cAMP pathway: Upon binding, GLP-1R activates stimulatory G-alpha-s (Gs) proteins, stimulating adenylyl cyclase to produce cyclic AMP (cAMP). Elevated cAMP activates two parallel effectors:

• PKA (Protein Kinase A): Phosphorylates CREB (cAMP response element-binding protein), promoting insulin gene transcription and beta-cell survival. PKA also closes K-ATP channels, triggering membrane depolarization and calcium-dependent insulin exocytosis.
• Epac2 (Exchange protein activated by cAMP): Activates Rap1/Rim2 signaling to potentiate glucose-dependent insulin granule release, providing an additional insulin secretion pathway independent of PKA.

Gq-dependent signaling: In the area postrema — a primary central target for semaglutide — Gq pathway activation contributes to appetite suppression. Semaglutide drives graded cAMP increases in GLP-1R-expressing neurons through both Gs-dependent and Gs-independent mechanisms, with phosphodiesterase 4 (PDE4) modulating these responses.

Hypothalamic appetite regulation: GLP-1R activation in the arcuate nucleus stimulates POMC (pro-opiomelanocortin) neurons that release alpha-MSH to promote satiety, while simultaneously inhibiting NPY/AgRP neurons that drive hunger. This dual neuronal modulation produces sustained appetite suppression beyond what gastric emptying delay alone can achieve.

Beyond Glucose: Multi-Organ Effects

• Cardiovascular: GLP-1R activation on cardiomyocytes and endothelial cells reduces oxidative stress and inflammation. Semaglutide suppresses NF-kB signaling through SIRT1-mediated deacetylation, reducing pro-inflammatory cytokine production. It also reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway.
• Hepatic: Ameliorates hepatic steatosis through improved insulin sensitivity via the PI3K/AKT pathway, enhanced fatty acid oxidation, and reduced de novo lipogenesis. Acts on LXR-alpha in liver cells to mediate cholesterol efflux through the LXR-alpha/ABCA1 pathway.
• Adipose tissue: Promotes white adipose tissue (WAT) browning through upregulation of UCP1 expression via AMPK/SIRT1 signaling. Modulates adipogenesis through C/EBP-alpha, SREBP1, and PPAR-gamma pathways.
• Renal: Reduces intraglomerular pressure, decreases albuminuria, and attenuates tubuloglomerular feedback, contributing to kidney protection observed in the FLOW trial.

Molecular Properties and Bioavailability

Property	Value
Molecular Formula	C187H291N45O59
Molecular Weight	~4,113.58 Da
CAS Number	910463-68-2
PubChem CID	56843331
Pharmacological Class	GLP-1 Receptor Agonist (EPC)
Half-life	~168 hours (7 days)
Bioavailability (SC)	~89%
Bioavailability (Oral)	~0.4-1% (with SNAC enhancer)
Protein Binding	>99% (albumin)
Metabolism	Proteolytic cleavage and beta-oxidation of fatty acid side chain
Elimination	Urine (~3%) and feces (~5%) as metabolites

Approved Formulations and Dosing

Ozempic (Subcutaneous Injection — Type 2 Diabetes)

• Starting dose: 0.25 mg once weekly for 4 weeks (initiation, not therapeutic)
• Maintenance: 0.5 mg once weekly; may increase to 1 mg then 2 mg weekly for additional glycemic control
• Administration: Subcutaneous injection in abdomen, thigh, or upper arm

Wegovy (Subcutaneous Injection — Weight Management and CV Risk Reduction)

• Dose escalation: 0.25 mg (weeks 1-4) -> 0.5 mg (weeks 5-8) -> 1.0 mg (weeks 9-12) -> 1.7 mg (weeks 13-16) -> 2.4 mg (week 17 onward)
• Maintenance: 2.4 mg once weekly
• Indication expanded (2024): Cardiovascular risk reduction in adults with established CVD and overweight/obesity

Rybelsus (Oral Tablet — Type 2 Diabetes)

• Doses: 3 mg (initiation), 7 mg, 14 mg daily
• How oral delivery works: Rybelsus uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), a 279-Da synthetic fatty acid derivative that enables oral peptide absorption. SNAC creates a concentrated microenvironment at the tablet-gastric mucosa interface, raising local pH from ambient gastric pH 1-2 to approximately pH 5+. This inactivates pepsin, protecting semaglutide from enzymatic degradation. SNAC then promotes transcellular absorption through epithelial membrane fluidization without disrupting tight junctions or causing mucosal damage. Despite the low oral bioavailability (~0.4-1%), semaglutide’s high potency and long half-life produce clinically meaningful outcomes.
• Must be taken: On an empty stomach with no more than 4 oz of plain water, at least 30 minutes before food, beverages, or other oral medications.

Clinical Evidence

Type 2 Diabetes: SUSTAIN Program

The SUSTAIN trials (1 through 10) established semaglutide as a leading treatment for type 2 diabetes. SUSTAIN-6 (Marso et al., 2016; PMID 27633186) was the cardiovascular outcomes trial, enrolling 3,297 patients with type 2 diabetes at high cardiovascular risk. Over a median 2.1-year follow-up, semaglutide reduced the composite MACE endpoint by 26% (HR 0.74; 95% CI 0.58-0.95). This included significant reductions in nonfatal stroke (39% reduction) and nonfatal myocardial infarction (26% reduction). HbA1c reductions across the SUSTAIN program ranged from 1.5% to 1.8%, consistently superior to comparators including sitagliptin, exenatide ER, and insulin glargine.

Obesity: STEP Program

The STEP (Semaglutide Treatment Effect in People with Obesity) trials demonstrated semaglutide 2.4 mg weekly as a transformative obesity treatment:

• STEP 1 (Wilding et al., 2021; PMID 33567185): 1,961 adults with BMI >=30 (or >=27 with comorbidity) without diabetes. Mean weight loss was 14.9% with semaglutide vs 2.4% with placebo at 68 weeks. Over one-third of participants achieved >=20% weight loss.
• STEP 2: Patients with type 2 diabetes achieved 9.6% weight loss (lower than non-diabetic populations, consistent with metabolic differences).
• STEP 3: Combined with intensive behavioral therapy, weight loss reached 16.0%.
• STEP 5: Extended to 104 weeks, confirming sustained weight loss of 15.2%.

Head-to-head data (Rubino et al., 2022; PMID 35015037) showed semaglutide 2.4 mg weekly produced significantly greater weight loss than liraglutide 3.0 mg daily.

Cardiovascular Outcomes: SELECT Trial

The SELECT trial (Lincoff et al., 2023; PMID 37952131) was a landmark cardiovascular outcomes study enrolling 17,604 adults aged >=45 with established cardiovascular disease and BMI >=27 but without diabetes. This was the first trial to demonstrate that a GLP-1 RA reduces cardiovascular events independent of diabetes treatment.

Key results at a mean follow-up of 39.8 months:

• 20% reduction in MACE (HR 0.80; 95% CI 0.72-0.90; P<0.001) — composite of cardiovascular death, nonfatal MI, and nonfatal stroke
• Weight loss sustained over 4 years: mean -10.2% body weight, -7.7 cm waist circumference
• Benefits were consistent across subgroups regardless of baseline BMI, age, sex, and race
• Discontinuation due to adverse events was 16.6% (semaglutide) vs 8.2% (placebo), primarily gastrointestinal

Kidney Outcomes: FLOW Trial

The FLOW trial (Perkovic et al., 2024; PMID 38785209) enrolled 3,533 patients with type 2 diabetes and chronic kidney disease (eGFR 25-75 mL/min/1.73m2 with albuminuria). The trial was stopped early for overwhelming efficacy at median 3.4 years follow-up:

• 24% reduction in major kidney disease events (HR 0.76; 95% CI 0.66-0.88; P=0.0003) — composite of kidney failure, >=50% eGFR reduction, or kidney/CV death
• 29% reduction in cardiovascular death (HR 0.71; 95% CI 0.56-0.89)
• 20% reduction in all-cause mortality (HR 0.80; 95% CI 0.67-0.95)
• Annual eGFR slope was 1.16 mL/min/1.73m2 less steep with semaglutide

Liver Disease: NASH/MASH

The phase 2 trial (Newsome et al., 2021; PMID 33185364) in biopsy-confirmed NASH with F1-F3 fibrosis showed semaglutide 0.4 mg daily achieved NASH resolution in 59% of patients vs 17% placebo (P<0.001), with 13% mean weight loss.

The phase 3 ESSENCE trial (2025; PMID 40305708) confirmed these results at scale: in 800 patients with MASH and F2-F3 fibrosis, semaglutide 2.4 mg weekly achieved:

• 62.9% MASH resolution without fibrosis worsening (vs 34.3% placebo)
• 36.8% fibrosis improvement without MASH worsening (vs 22.4% placebo)
• 32.7% achieved both MASH resolution and fibrosis improvement (vs 16.1% placebo)
• Mean weight loss of 10.5% (vs 2.0% placebo)

Alzheimer’s Disease: EVOKE Trials

The EVOKE and EVOKE+ phase 3 trials enrolled 3,808 participants with early Alzheimer’s disease (MCI or mild dementia) with confirmed amyloid pathology. Results presented in late 2025 showed semaglutide did not meet primary endpoints for slowing cognitive decline or time to progression to dementia. However, semaglutide reduced several AD-relevant cerebrospinal fluid biomarkers by up to 10%, including pTau181, pTau217, and neuroinflammation marker YKL-40. Real-world observational data (Wang et al., 2024) separately showed associations between semaglutide use and lower risk of first-time Alzheimer’s diagnosis in type 2 diabetes patients, suggesting potential preventive rather than therapeutic effects.

Drug Interactions and Contraindications

Boxed Warning: Thyroid C-Cell Tumors

In rodent studies, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant exposures. Human relevance is unknown. Semaglutide is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Patients should be counseled about MTC symptoms: neck mass, dysphagia, dyspnea, persistent hoarseness.

Pancreatitis

Acute pancreatitis, including fatal hemorrhagic and necrotizing forms, has been reported with GLP-1 receptor agonists including semaglutide. Semaglutide has not been studied in patients with a history of pancreatitis. If pancreatitis is suspected (persistent severe abdominal pain, sometimes radiating to back, with or without vomiting), semaglutide should be discontinued immediately and not restarted.

Drug Interactions

• Insulin and sulfonylureas: Increased risk of hypoglycemia. Consider dose reduction of insulin or sulfonylureas when initiating semaglutide.
• Oral medications: Semaglutide delays gastric emptying and may affect the rate and extent of absorption of concomitantly administered oral medications. Use with caution, particularly with medications that have a narrow therapeutic index.
• Oral contraceptives: Potential for reduced absorption; monitor for breakthrough bleeding.
• Warfarin: Monitor INR more frequently when initiating or changing semaglutide dose.

Additional Precautions

• Diabetic retinopathy: SUSTAIN-6 observed increased diabetic retinopathy complications with rapid glycemic improvement. Monitor patients with existing retinopathy.
• Gallbladder disease: Substantial or rapid weight loss can increase risk of cholelithiasis. Monitor for gallbladder-related symptoms.
• Renal impairment: GI adverse events (nausea, vomiting, diarrhea) may cause dehydration, which can worsen renal function. Monitor in patients with renal impairment.
• Pregnancy: Contraindicated. Discontinue at least 2 months before planned pregnancy due to prolonged washout period.

Active Clinical Trials

Semaglutide continues to be investigated in multiple ongoing trials:

1. PRECIDENTD (NCT05390892) — 6,000-patient pragmatic trial comparing SGLT2 inhibitors vs GLP-1 RAs for cardiovascular and kidney outcomes in type 2 diabetes
2. EPIC-CT (NCT07297589) — Phase 3 trial comparing dapagliflozin and semaglutide effects on epicardial cardiac fat post-myocardial infarction
3. SWEET Study (NCT04873050) — Phase 4 trial evaluating semaglutide for normoglycemia regression in women with recent gestational diabetes
4. PORT Study (NCT05071898) — Pharmacogenetics of GLP-1 RA response, identifying genetic variants associated with semaglutide efficacy
5. Weight maintenance post-cessation (NCT07092618) — Phase 2/3 trial investigating alternative therapies for maintaining weight loss after GLP-1 medication discontinuation

Safety and Side Effects

The most common adverse events across all semaglutide trials are gastrointestinal in nature, typically emerging during dose escalation and improving with continued treatment:

• Nausea: 20-44% (vs 6-16% placebo), most common during dose escalation
• Diarrhea: 15-30% (vs 10-16% placebo)
• Vomiting: 6-24% (vs 2-6% placebo)
• Constipation: 10-24% (vs 6-12% placebo)
• Abdominal pain: 6-20%
• Injection site reactions: 0.2-1% (subcutaneous formulations)
• Fatigue and dizziness: Reported at higher rates than placebo

In the SELECT trial, adverse events leading to permanent treatment discontinuation occurred in 16.6% of the semaglutide group vs 8.2% placebo, with gastrointestinal disorders accounting for 10.0% of discontinuations in the semaglutide arm. Despite higher GI event rates, semaglutide demonstrated a favorable overall benefit-risk profile across all approved indications.